Compare Charles River Laboratories Intl. Inc (CRL) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Alliant Energy Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Alliant Energy Corporation trades at $74.63 (market cap $19.71B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 2.73% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | LNT | |
|---|---|---|
Market Cap | $11.14B | $19.71B |
Sector | Health | Utilities |
52-Week High | $233.60 | $78.03 |
52-Week Low | $145.57 | $62.87 |
Enterprise Value | $14.00B | $31.43B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Alliant Energy (LNT) trades at $76.63, up 0.3% today, near the consensus price target of $76.50. The stock shows a bullish technical trend with strong moving average signals. Recent earnings have mostly beaten estimates, with Q1 2026 EPS of $0.82 exceeding expectations. The company's $13.4 billion clean energy investment plan aims to capitalize on data center demand and drive 5-7% annual earnings growth, supported by rising operating cash flow and a solid 18.58% net income margin.
LNT presents a balanced opportunity with steady utility earnings and growth initiatives, but faces risks from high capital expenditure and rising debt levels. Analyst sentiment is positive with a 52% buy rating, though the stock's valuation multiples like a P/E of 24.1 suggest limited near-term upside without significant earnings acceleration. Regulatory approvals and execution on its investment plan are critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
